Breast Cancer Coverage from Every Angle

Recent News

AACR COVID-19: Balancing Risks and Benefits of Surgery for Breast Cancer
FDA Accepts Two Applications for Pembrolizumab in Triple-Negative Breast Cancer
FDA Approves Breast Cancer Companion Diagnostic for Trastuzumab Therapy
AACR COVID-19: Adjustments in Use of CDK4/6 Inhibitors for Metastatic Breast Cancer
Collaborative Palliative Care Intervention for Women With Metastatic Breast Cancer
AACR COVID-19: National Survey of Patient Concerns Regarding Breast Cancer
AACR COVID-19: Recent Trends in Screening for Breast Cancer
BYLieve Trial Supports Use of Alpelisib Plus Fulvestrant for Some Breast Cancers
AACR II: Six New Risk Loci for Breast Cancer Identified in Women of African Ancestry
3-Year TRAIN-2 Update on Neoadjuvant Therapy for HER2-Positive Breast Cancer
AACR II: ARTEMIS Trial of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Can Artificial Intelligence Improve the Accuracy of Screening Mammography Assessment?
Biomarker-Based Update on Neoadjuvant Letrozole With or Without Ribociclib
Neoadjuvant Endocrine Therapy for Locally Advanced Breast Cancer
AACR II: Adding Interferon-Gamma to Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer
Combining IL-7 With Pembrolizumab in Metastatic Triple-Negative Breast Cancer
Subcutaneous Combination Therapy Approved by FDA for HER2-Positive Breast Cancer
AACR II: Study Finds Race-Based Survival Differences in Triple-Negative Breast Cancer
First-in-Human Clinical Trial of Microsurgery Robot to Treat Breast Cancer–Related Lymphedema
ASCO20: Tucatinib Combination Therapy for Breast Cancer With Brain Metastases
ASCO20: KEYNOTE-355 Trial of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ASCO20: Does Adding Trastuzumab to Radiotherapy Decrease Recurrence of Breast Cancer?
ASCO20: Which Women With HER2-Positive Early Breast Cancer May Avoid Chemotherapy?
ASCO20: Adding Veliparib to Cisplatin for Select Metastatic Triple-Negative Breast Cancers
ASCO20: MINDACT Update Supports Longer-Term Use of MammaPrint in Clinical Decision-Making
ASCO20: Evaluating Palbociclib Plus Fulvestrant or Letrozole in Metastatic Breast Cancer
ASCO20: Biomarker Expression and Outcomes After Adjuvant Treatment in Breast Cancer
ASCO20: Can Local Therapy Improve Survival in Newly Diagnosed Advanced Breast Cancer?
ASCO20: Adding T-DM1 to Targeted Therapy for High-Risk Early Breast Cancer
ASBrS 2020: Cosmetic Outcomes With Breast-Conserving Therapy
ASBrS 2020: Is Age Associated With the Presentation of Aggressive Breast Cancer?
Therapeutic Nanoparticles for Primary and Metastatic Breast Tumors
Cardiac Dysfunction Related to Breast Cancer Treatment
Single-Cell RNA Sequencing Suggests Oxidative Phosphorylation May Promote Breast Cancer Metastasis
Radiotherapy-Induced Tumors and Li-Fraumeni Syndrome in Patients With Breast Cancer
AACR 2020: Talazoparib Versus Chemotherapy in HER2-Negative Advanced Breast Cancer
DDW 2020: One-Stop Multicancer Screening Program
AACR 2020: Can Fasting Enhance Endocrine Therapy in Breast Cancer?
AACR 2020: Combination Immunotherapy for Triple-Negative Breast Cancer
Does High Fiber Consumption Reduce the Risk of Breast Cancer?
AACR 2020: Lapatinib-Based First-Line Treatment in Metastatic Breast Cancer
TUBB3 Gene Expression: Prognostic Biomarker for Breast Cancer Stage?
Racial Disparity in Clinical Trials of Immunotherapeutics for Breast Cancer
Antibody-Drug Conjugate Receives FDA Approval in Metastatic Triple-Negative Breast Cancer
Consortium Offers Breast Cancer Treatment Recommendations During COVID-19 Pandemic
FDA Approves Tucatinib in Combination Therapy for Metastatic Breast Cancer
SGO 2020: For BRCA-Mutation Carriers, Breast Cancer May Follow Ovarian Cancer
ACC 2020: Can Statins Lower the Rate of Heart Failure After Breast Cancer Treatment?
Improving Patient Care and Self-Management Pathways for Breast Cancer: The 4R Model
ACC 2020: Potential Biomarker of Cardiac Dysfunction in Patients Treated for Breast Cancer
Breast Cancer Treatment Outcomes Across Racial Subgroups: Talazoparib Versus Chemotherapy
Androgen Receptor Agonism in Estrogen Receptor–Positive Breast Cancer
Type 2 Diabetes and Recurrence of Breast Cancer in Older Women
Trastuzumab Biosimilar Receives FDA Approval of Multidose Vial
Predicting Residual Breast Cancer After Neoadjuvant Chemotherapy
TAT 2020: Predictive Biomarker for FGFR Inhibitors in Breast Cancer
Digital Breast Tomosynthesis Versus Digital Mammography: Long-Term Outcomes
TAT 2020: TTK Inhibitor Plus Paclitaxel in Advanced HER2-Negative Breast Cancer
ASCO and CAP Issue Guideline Update on Endocrine Receptor Testing in Breast Cancer
MINDACT Trial of Adjuvant Chemotherapy for Early Luminal Breast Cancer: Does Age Matter?
10-Year Follow-up on Anastrozole in Prevention of Breast Cancer
Neratinib Plus Capecitabine Approved by FDA in HER2-Positive Metastatic Breast Cancer
FDA Accepts BLA for Fixed-Dose Combination Therapy for HER2-Positive Breast Cancer
Physical Activity and Quality of Life After Radiation Therapy for Breast Cancer
Estrogen vs Estrogen Plus Progestin Use in Postmenopausal Women
Tucatinib Receives FDA Priority Review in HER2-Positive Breast Cancer
10-Year Findings With Letrozole in Hormone Receptor–Positive Breast Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.